CorMedix commercializes DefenCath (taurolidine and heparin), an antimicrobial catheter lock solution designed to reduce catheter-related bloodstream infections in adult hemodialysis patients with central venous catheters. The product addresses a hospital and dialysis-clinic infection-control niche rather than a broad primary-care drug franchise. Its commercial focus is specialty distribution into U.S. dialysis and acute-care settings.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 39.1 | — | 20.5 | — |
| Q2 2025 | 39.7 | — | 19.8 | — |
| Q3 2025 | 104.3 | — | 108.6 | — |
| Q4 2025 | 128.6 | — | 13 | -2.4% |
| Q1 2026 | 127.4 | 226.1% | 38.4 | 87% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Vinci Compass Investments Ltd. (VINP), Aquestive Therapeutics, Inc. (AQST), Village Super Market, Inc. (VLGEA), Kearny Financial Corp. (KRNY), Yuanbao Inc. (YB), Sagimet Biosciences Inc. (SGMT)